Cargando…

Capreomycin is active against non-replicating M. tuberculosis

BACKGROUND: Latent tuberculosis infection (LTBI) is affecting one-third of the world population, and activation of LTBI is a substantial source of new cases of tuberculosis. LTBI is caused by tubercle bacilli in a state of non-replicating persistence (NRP), and the goal of this study was to evaluate...

Descripción completa

Detalles Bibliográficos
Autores principales:	Heifets, Leonid, Simon, Julie, Pham, Van
Formato:	Texto
Lenguaje:	English
Publicado:	BioMed Central 2005
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1083412/ https://www.ncbi.nlm.nih.gov/pubmed/15804353 http://dx.doi.org/10.1186/1476-0711-4-6

Ejemplares similares

The structures of the anti-tuberculosis antibiotics viomycin and capreomycin bound to the 70S ribosome
por: Stanley, Robin E., et al.
Publicado: (2010)

Spray-Dried Powder Formulation of Capreomycin Designed for Inhaled Tuberculosis Therapy
por: Shao, Zitong, et al.
Publicado: (2021)

Capreomycin-induced optic neuritis in a case of multidrug resistant pulmonary tuberculosis
por: Magazine, Rahul, et al.
Publicado: (2010)

Evaluation of Susceptibility of the Human Pathogen Helicobacter pylori to the Antibiotic Capreomycin
por: Sukati, Suriyan, et al.
Publicado: (2022)

Evaluation of Genetic Mutations Associated with Mycobacterium tuberculosis Resistance to Amikacin, Kanamycin and Capreomycin: A Systematic Review
por: Georghiou, Sophia B., et al.
Publicado: (2012)

Molecular characterization of amikacin, kanamycin and capreomycin resistance in M/XDR-TB strains isolated in Thailand
por: Sowajassatakul, Angkanang, et al.
Publicado: (2014)

Activity of Trifluoperazine against Replicating, Non-Replicating and Drug Resistant M. tuberculosis
por: Advani, Meeta J., et al.
Publicado: (2012)

Co-Delivery of D-LAK Antimicrobial Peptide and Capreomycin as Inhaled Powder Formulation to Combat Drug-Resistant Tuberculosis
por: Shao, Zitong, et al.
Publicado: (2023)

High Frequency of Resistance, Lack of Clinical Benefit, and Poor Outcomes in Capreomycin Treated South African Patients with Extensively Drug-Resistant Tuberculosis
por: Pietersen, Elize, et al.
Publicado: (2015)

Assessment of Amikacin- and Capreomycin-Related Adverse Drug Reactions in Patients with Multidrug-Resistant Tuberculosis and Exploring the Role of Genetic Factors
por: Freimane, Lauma, et al.
Publicado: (2023)

Rifampin- or Capreomycin-Induced Remodeling of the Mycobacterium smegmatis Mycolic Acid Layer Is Mitigated in Synergistic Combinations with Cationic Antimicrobial Peptides
por: Man, DeDe Kwun-Wai, et al.
Publicado: (2018)

A class of hydrazones are active against non-replicating Mycobacterium tuberculosis
por: Bonnett, Shilah A., et al.
Publicado: (2018)

The Differential Gene Expression Pattern of Mycobacterium tuberculosis in Response to Capreomycin and PA-824 versus First-Line TB Drugs Reveals Stress- and PE/PPE-Related Drug Targets
por: Fu, Li M., et al.
Publicado: (2009)

Rapid Diagnosis of Drug Resistance to Fluoroquinolones, Amikacin, Capreomycin, Kanamycin and Ethambutol Using Genotype MTBDRsl Assay: A Meta-Analysis
por: Feng, Yan, et al.
Publicado: (2013)

InhA inhibitors have activity against non-replicating Mycobacterium tuberculosis
por: Flint, Lindsay, et al.
Publicado: (2020)

Crystal structure of the α-ketoglutarate-dependent non-heme iron oxygenase CmnC in capreomycin biosynthesis and its engineering to catalyze hydroxylation of the substrate enantiomer
por: Hsiao, Yu-Hsuan, et al.
Publicado: (2022)

Benzene Amide Ether Scaffold is Active against Non-replicating and Intracellular Mycobacterium tuberculosis
por: Ahmed, Sara, et al.
Publicado: (2023)

A rapid, low pH, nutrient stress, assay to determine the bactericidal activity of compounds against non-replicating Mycobacterium tuberculosis
por: Early, Julie V., et al.
Publicado: (2019)

Comparison of Serum Potassium, MagnEsium, and Calcium Levels between Kanamycin and Capreomycin-BASEd Regimen-Treated MultiDrug-Resistant TuBerculosis Patients in Bandung (CEASE MDR-TB): A Retrospective Cohort Study
por: Soeroto, Arto Yuwono, et al.
Publicado: (2019)

Nitrobenzoates and Nitrothiobenzoates with Activity against M. tuberculosis
por: Pais, João P., et al.
Publicado: (2023)

Rapid, Semiquantitative Assay To Discriminate among Compounds with Activity against Replicating or Nonreplicating Mycobacterium tuberculosis
por: Gold, Ben, et al.
Publicado: (2015)

Targeting DNA Replication and Repair for the Development of Novel Therapeutics against Tuberculosis
por: Reiche, Michael A., et al.
Publicado: (2017)

A rhodanine agent active against non-replicating intracellular Mycobacterium avium subspecies paratuberculosis
por: Bull, Tim J, et al.
Publicado: (2009)

Identification of Novel Mt-Guab2 Inhibitor Series Active against M. tuberculosis
por: Usha, Veeraraghavan, et al.
Publicado: (2012)

M. tuberculosis enhances its virulence during replication in blood from HIV patients
por: Ryndak, Michelle B, et al.
Publicado: (2014)

Bis-biguanide dihydrochloride inhibits intracellular replication of M. tuberculosis and controls infection in mice
por: Shen, Hongbo, et al.
Publicado: (2016)

IgG, IgM and IgA antibodies against the novel polyprotein in active tuberculosis
por: Feng, Xiaoyan, et al.
Publicado: (2014)

Novel Screen to Assess Bactericidal Activity of Compounds Against Non-replicating Mycobacterium abscessus
por: Berube, Bryan J., et al.
Publicado: (2018)

Interferon-Gamma Improves Macrophages Function against M. tuberculosis in Multidrug-Resistant Tuberculosis Patients
por: Khan, Taj Ali, et al.
Publicado: (2016)

Lack of intracellular replication of M. tuberculosis and M. bovis BCG caused by delivering bacilli to lysosomes in murine brain microvascular endothelial cells
por: Chen, Xi, et al.
Publicado: (2015)

Dual Neonate Vaccine Platform against HIV-1 and M. tuberculosis
por: Hopkins, Richard, et al.
Publicado: (2011)

N-terminus of M2 protein could induce antibodies with inhibitory activity against influenza virus replication
por: Liu, Wanli, et al.
Publicado: (2003)

INGOT-DR: an interpretable classifier for predicting drug resistance in M. tuberculosis
por: Zabeti, Hooman, et al.
Publicado: (2021)

Fragment-Based Whole Cell Screen Delivers Hits against M. tuberculosis and Non-tuberculous Mycobacteria
por: Moreira, Wilfried, et al.
Publicado: (2016)

Non-Replicating Mycobacterium tuberculosis Elicits a Reduced Infectivity Profile with Corresponding Modifications to the Cell Wall and Extracellular Matrix
por: Bacon, Joanna, et al.
Publicado: (2014)

Persisting PET-CT lesion activity and M. tuberculosis mRNA after pulmonary tuberculosis cure
por: Malherbe, Stephanus T., et al.
Publicado: (2016)

Transcriptional and Physiological Changes during Mycobacterium tuberculosis Reactivation from Non-replicating Persistence
por: Du, Peicheng, et al.
Publicado: (2016)

Targeting Non-Replicating Mycobacterium tuberculosis and Latent Infection: Alternatives and Perspectives (Mini-Review)
por: Egorova, Anna, et al.
Publicado: (2021)

Latent Tuberculosis: A Promising New Compound to Treat Non-Replicating and Intramacrophagic Mycobacteria
por: Campos, Débora Leite, et al.
Publicado: (2022)

Mycobacterium tuberculosis replicates within necrotic human macrophages
por: Lerner, Thomas R., et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_3vbd79fko5pb5jllt55ndri91c